Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY M SOBELL

Allopathic & Osteopathic Physicians Dermatology

NPI
1154383610
CMS profile
51651
Location
CHESTNUT HILL, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$157,462.69

257 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY M SOBELL

NPI 1154383610 · CMS profile ID 51651

Allopathic & Osteopathic Physicians / Dermatology

CHESTNUT HILL, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154383610?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY M SOBELL, NPI 1154383610, CMS profile ID 51651. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154383610?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEFFREY M SOBELL, NPI 1154383610, CMS profile ID 51651. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154383610?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEFFREY M SOBELL, NPI 1154383610, CMS profile ID 51651, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1154383610?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

257 matching records · $157,462.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 257 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 257.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $10.7110/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078692883 CMS
Janssen Biotech, Inc. $6.3110/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078692939 CMS
Regeneron Healthcare Solutions, Inc. $120.9610/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114183508 CMS
UCB, Inc. $2,075.0010/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303212 CMS
Janssen Biotech, Inc. $1,800.0010/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078692723 CMS
Regeneron Healthcare Solutions, Inc. $108.7510/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114183498 CMS
E.R. Squibb & Sons, L.L.C. $27.9910/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101641913 CMS
Lilly USA, LLC $6,800.0010/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1155953888 CMS
Lilly USA, LLC $113.3210/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135038843 CMS
Lilly USA, LLC $132.5010/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135060126 CMS
Lilly USA, LLC $298.1010/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135060230 CMS
Lilly USA, LLC $31.5410/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155179685 CMS
Lilly USA, LLC $25.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155179687 CMS
Lilly USA, LLC $25.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155179823 CMS
Lilly USA, LLC $55.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155179825 CMS
Lilly USA, LLC $42.3610/17/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155179827 CMS
Lilly USA, LLC $83.4110/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155179829 CMS
Lilly USA, LLC $269.0010/17/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155187203 CMS
Lilly USA, LLC $140.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155952376 CMS
Lilly USA, LLC $31.5410/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155952378 CMS
Lilly USA, LLC $49.5510/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155953570 CMS
Lilly USA, LLC $25.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155956032 CMS
Lilly USA, LLC $0.3410/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155958604 CMS
Lilly USA, LLC $20.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155958606 CMS
Lilly USA, LLC $25.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155959416 CMS
Lilly USA, LLC $0.1410/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155959418 CMS
Lilly USA, LLC $119.8210/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155959678 CMS
Lilly USA, LLC $54.0510/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155959680 CMS
Lilly USA, LLC $25.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155960918 CMS
Janssen Biotech, Inc. $117.0210/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078692647 CMS
Arcutis Biotherapeutics, Inc. $15.6310/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121052773 CMS
ABBVIE INC. $134.8810/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106132448 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1.8610/09/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155489715 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $0.3710/09/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155489717 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $28.6810/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152158571 CMS
Regeneron Healthcare Solutions, Inc. $327.0010/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114183492 CMS
PFIZER INC. $16.2210/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131924890 CMS
UCB, Inc. $24.1210/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303203 CMS
UCB, Inc. $4,500.0010/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303207 CMS
UCB, Inc. $131.2509/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153142099 CMS
E.R. Squibb & Sons, L.L.C. $4,340.0009/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101641884 CMS
Janssen Biotech, Inc. $6.2009/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078692659 CMS
Janssen Biotech, Inc. $13.0709/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078692734 CMS
UCB, Inc. $2,075.0009/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303198 CMS
Lilly USA, LLC $1.6509/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135038847 CMS
Lilly USA, LLC $30.4209/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135055346 CMS
UCB, Inc. $74.9409/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303194 CMS
UCB, Inc. $2,075.0009/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303190 CMS
Janssen Biotech, Inc. $1,800.0009/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078693031 CMS
GENZYME CORPORATION $23.6809/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139647402 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $200,427.14 343
PY2020 $84,220.21 117
PY2021 $71,930.98 121
PY2022 $94,217.99 143
PY2023 $209,251.95 288
PY2024 $157,462.69 257
PY2025 $168,026.87 283

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $166,741.82 27
PY2024 Principal investigator $187,687.13 11
PY2023 Principal investigator $36,618.68 8
PY2022 Principal investigator $31,052.60 3
PY2021 Principal investigator $38,060.50 3
PY2020 Recipient $575.00 1
PY2020 Principal investigator $52,526.06 10
PY2019 Recipient $7,197.32 2
PY2019 Principal investigator $107,702.87 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,518.00 12/25/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305476
Principal investigator 1 PFIZER INC. $10,190.49 12/25/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228749509
Principal investigator 1 PFIZER INC. $2,926.13 12/17/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228747994
Principal investigator 1 PFIZER INC. $10,190.49 12/11/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228749184
Principal investigator 1 Janssen Research & Development, LLC $8,597.00 12/01/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305454
Principal investigator 1 PFIZER INC. $14,528.72 11/26/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228728015
Principal investigator 1 ABBVIE INC. $1,262.20 11/04/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423205
Principal investigator 1 ABBVIE INC. $500.00 10/30/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423201
Principal investigator 1 Janssen Research & Development, LLC $4,518.00 10/24/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305425
Principal investigator 1 Janssen Research & Development, LLC $27,625.00 10/17/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305486
Principal investigator 1 Janssen Research & Development, LLC $2,748.00 10/17/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305550
Principal investigator 1 ABBVIE INC. $1,110.20 10/10/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423193
Principal investigator 1 Janssen Research & Development, LLC $2,259.00 09/29/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305409
Principal investigator 1 PFIZER INC. $25,050.00 09/09/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228761944
Principal investigator 1 Janssen Research & Development, LLC $9,594.00 09/08/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175305508
Principal investigator 1 ABBVIE INC. $1,864.70 09/03/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 08/07/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184137507
Principal investigator 1 ABBVIE INC. $318.80 08/05/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423144
Principal investigator 1 Eli Lilly and Company $3,012.00 06/16/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187877423
Principal investigator 1 ABBVIE INC. $1,262.20 06/03/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423121
Principal investigator 1 ABBVIE INC. $1,864.70 05/06/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423105
Principal investigator 1 ABBVIE INC. $1,262.20 04/03/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423090
Principal investigator 1 ABBVIE INC. $17,932.20 02/25/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423062
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,540.77 02/14/2025 Covered Recipient Teaching Hospital
Tufts Medical Center
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1236000090
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,121.12 01/17/2025 Non-covered Recipient Entity
Ora
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235994844
Principal investigator 1 ABBVIE INC. $3,000.00 01/07/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423037
Principal investigator 1 ABBVIE INC. $1,445.90 01/02/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202423033